MedPath

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

Phase 3
Completed
Conditions
HIV Infections
Registration Number
NCT00002320
Lead Sponsor
Glaxo Wellcome
Brief Summary

To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients.

PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.

Detailed Description

Patients are randomized to one of four treatment arms: 3TC alone, AZT alone, low-dose 3TC plus AZT, or high-dose 3TC plus AZT. Patients receive treatment for 32 weeks, with possible extension to 52 weeks.

PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
320
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (22)

Combat Group

🇺🇸

Los Angeles, California, United States

San Diego Community Research Group

🇺🇸

San Diego, California, United States

Pacific Oaks Med Group

🇺🇸

Sherman Oaks, California, United States

Harbor - UCLA Med Ctr

🇺🇸

Torrance, California, United States

Infectious Disease Research Institute Inc

🇺🇸

Tampa, Florida, United States

AIDS Research Consortium of Atlanta

🇺🇸

Atlanta, Georgia, United States

Chicago Ctr for Clinical Research

🇺🇸

Chicago, Illinois, United States

Louisiana Cardiovascular Research Ctr

🇺🇸

New Orleans, Louisiana, United States

CRI of New England

🇺🇸

Brookline, Massachusetts, United States

Saint Luke's - Roosevelt Hosp Ctr

🇺🇸

New York, New York, United States

Scroll for more (12 remaining)
Combat Group
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.